Retinitis Pigmentosa Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight's, "Retinitis Pigmentosa Pipeline Insight 2024" report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our comprehensive Retinitis Pigmentosa Pipeline Report to stay informed about the latest advancements. Download copy now @ Retinitis Pigmentosa Pipeline Outlook [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Retinitis Pigmentosa Pipeline Report

* In September 2024:- Janssen Research & Development LLC- Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
* In September 2024:- AAVantgarde Bio Srl- A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa. The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
* DelveInsight's Retinitis Pigmentosa pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
* The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye , and others.
* Promising Retinitis Pigmentosa Therapies such as EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001 , and others.

Dive into our Retinitis Pigmentosa Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Retinitis Pigmentosa Treatment Therapies [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Retinitis Pigmentosa Emerging Drugs Profile

* BIIB-112: Biogen

BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.

* QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.

Download the Retinitis Pigmentosa Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Retinitis Pigmentosa Clinical Trials Assessment [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type

Retinitis Pigmentosa Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Dive into our detailed Retinitis Pigmentosa Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Retinitis Pigmentosa Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Retinitis Pigmentosa Pipeline Report

* Coverage- Global
* Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
* Retinitis Pigmentosa Therapies- EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001, and others.
* Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Gain valuable insights into emerging therapies and innovations with our Retinitis Pigmentosa Pipeline Report @ Retinitis Pigmentosa Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Retinitis Pigmentosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Retinitis Pigmentosa - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Retinitis Pigmentosa Collaboration Deals
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BIIB-112: Biogen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* N-acetylcysteine-amide: Nacuity Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SPVN 06: SparingVision
* Drug profiles in the detailed report.....
* Inactive Products
* Retinitis Pigmentosa Key Companies
* Retinitis Pigmentosa Key Products
* Retinitis Pigmentosa- Unmet Needs
* Retinitis Pigmentosa- Market Drivers and Barriers
* Retinitis Pigmentosa- Future Perspectives and Conclusion
* Retinitis Pigmentosa Analyst Views
* Retinitis Pigmentosa Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinitis-pigmentosa-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.